Tin tức & Cập nhật
Xem bài viết Hô hấp
Xem
Chỉ hiển thị Multimedia

Nerandomilast slows IPF progression in patients already on antifibrotic therapy
11 Jul 2025
bởiElvira Manzano
The novel oral PDE4B* inhibitor nerandomilast slows the progression of idiopathic pulmonary fibrosis (IPF) in patients receiving antifibrotic treatment, as shown in the phase III FIBRONEER-IPF trial.
Nerandomilast slows IPF progression in patients already on antifibrotic therapy
11 Jul 2025
MMP7 predicts progression, death in antifibrotic-treated IPF
28 Jun 2025
bởiStephen Padilla
Higher levels of matrix metalloprotease 7 (MMP7) pretreatment are predictive of 12-month progression and mortality among patients with idiopathic pulmonary fibrosis (IPF) who have been treated with antifibrotics, reveals a recent study.







